

Special Issue

Pharmacogenetics and Pharmacogenomics: Driving Forces in Modern Precision Medicine

Message from the Guest Editors

Pharmacogenetics and pharmacogenomics have emerged as pivotal components of modern precision medicine, enabling the optimization of therapeutic interventions through the understanding of individual genetic variability. This Special Issue aims to highlight innovative research and comprehensive reviews that explore the role of genetic and genomic factors in modulating drug response, toxicity, and treatment outcomes. We welcome contributions on a wide range of topics, including the identification and clinical implementation of pharmacogenetic biomarkers, the development and application of polygenic risk scores in predicting drug response, and studies addressing phenoconversion and its impact on drug metabolism and therapeutic efficacy. Additionally, we invite submissions that explore methodological advances, real-world implementation strategies, and the integration of pharmacogenomics into clinical guidelines. This Special Issue seeks to provide a comprehensive and inclusive overview of current progress in the field, aiming to bridge the gap between genomic research and clinical practice in the pursuit of truly personalized medicine.

Guest Editors

Dr. Miriam Saiz-Rodríguez

1. Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain
2. Facultad de Ciencias de la Salud, Universidad de Burgos, 09002 Burgos, Spain

Dr. Dora Koller

1. Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, Barcelona, Catalonia, Spain
2. Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/243200

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).